HER kinase inhibition in patients with HER2-and HER3-mutant cancers

Hyman, DM; Piha-Paul, SA; Won, H; Rodon, J; Saura, C; Shapiro, GI; Juric, D; Quinn, DI; Moreno, V; Doger, B; Mayer, IA; Boni, V; Calvo, E; Loi, S; Lockhart, AC; Erinjeri, JP; Scaltriti, M; Ulaner, GA; Patel, J; Tang, JB; Beer, H; Selcuklu, SD; Hanrah

Hyman, DM (reprint author), Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA.

NATURE, 2018; 554 (7691): 189

Abstract

Somatic mutations of ERBB2 and ERBB3 (which encode HER2 and HER3, respectively) are found in a wide range of cancers. Preclinical modelling suggests t......

Full Text Link